Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000169408 | SCV000220811 | likely pathogenic | Primary hyperoxaluria, type I | 2014-10-16 | criteria provided, single submitter | literature only | |
Department Of Genetics, |
RCV000169408 | SCV000891624 | likely pathogenic | Primary hyperoxaluria, type I | 2017-12-30 | criteria provided, single submitter | curation | |
Labcorp Genetics |
RCV001236818 | SCV001409555 | pathogenic | not provided | 2024-03-13 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 116 of the AGXT protein (p.Gly116Arg). This variant is present in population databases (rs180177207, gnomAD 0.003%). This missense change has been observed in individual(s) with primary hyperoxaluria (PMID: 10453743, 17460142, 25629080, 26252291, 33691640). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 189021). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on AGXT protein function. For these reasons, this variant has been classified as Pathogenic. |
Kariminejad - |
RCV001814082 | SCV001755665 | likely pathogenic | Abnormality of metabolism/homeostasis | 2021-07-10 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000169408 | SCV004192761 | pathogenic | Primary hyperoxaluria, type I | 2024-02-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000169408 | SCV005651599 | likely pathogenic | Primary hyperoxaluria, type I | 2023-12-27 | criteria provided, single submitter | clinical testing | |
Clinical Biochemistry Laboratory, |
RCV000169408 | SCV000239632 | pathogenic | Primary hyperoxaluria, type I | 2014-11-27 | no assertion criteria provided | in vitro | |
Natera, |
RCV000169408 | SCV002076457 | likely pathogenic | Primary hyperoxaluria, type I | 2020-11-03 | no assertion criteria provided | clinical testing |